skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Management of Medication Toxicity or Intolerance

Hematologic Effects

(Last updated: February 12, 2014; last reviewed: February 12, 2014)

 Click here to view this table as an image

Table 11d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
Adverse Effects Associated ARVs Onset/Clinical Manifestations Estimated Frequency Risk Factors Prevention/ Monitoring Management
Anemiaa Principally ZDV Onset:
  • Variable, weeks to months
Presentation
Most Commonly:
  • Asymptomatic or mild fatigue
  • Pallor
  • Tachypnea 
Rarely:
  • Congestive heart failure
HIV-Exposed Newborns:
  • Severe anemia uncommon, but may be seen coincident with physiologic Hgb nadir
HIV-Infected Children on ARVs:
  • 2–3 times more common with ZDV-containing regimens; less frequent with currently recommended dosing of ZDV
HIV-Exposed Newborns:
  • Premature birth
  • In utero exposure to ARVs
  • Advanced maternal HIV
  • Neonatal blood loss
  • Concurrent ZDV plus 3TC neonatal prophylaxis
HIV-Infected Children on ARVs:
  • Underlying hemoglobinopathy (sickle cell disease, G6PD deficiency)
  • Myelosuppressive drugs (e.g., TMP-SMX, rifabutin)
  • Iron deficiency
  • Advanced or poorly controlled HIV disease
HIV-Exposed Newborns:
  • Obtain CBC at birth.
  • Consider repeat CBC at 4 weeks for neonates who are at higher risk (e.g., those born prematurely or known to have low birth Hgb).
HIV-Infected Children on ARVs:
  • Avoid ZDV in children with moderate to severe anemia when alternative agents are available.
  • Obtain CBC as part of routine care.
HIV-Exposed Newborns:
  • Rarely require intervention unless Hgb is <7.0 g/dL or anemia is associated with symptoms.
  • Consider discontinuing ZDV if 4 weeks or more of a 6-week ZDV prophylaxis regimen are already completed (see the Perinatal Guidelinesb).
HIV-Infected Children on ARVs:
  • Discontinue non-ARV, marrow-toxic drugs, if feasible.
  • Treat coexisting iron deficiency, OIs, malignancies.
  • For persistent severe anemia thought to be associated with ARVs, change to a non-ZDV-containing regimen; consider a trial of erythropoietin if essential to continue ZDV.
Macrocytosis
Principally ZDV; also d4T
Onset:
  • Within days to weeks of starting therapy
  • MCV often >100 fL
Presentation:
  • Most often asymptomatic
  • Sometimes associated with anemia (occurs more often with ZDV than with d4T)
>90-95%, all ages
None Obtain CBC as part of routine care
None required unless associated with anemia
Neutropeniaa Principally
ZDV
Onset:
  • Variable
Presentation:
  • Most commonly asymptomatic. Complications appear to be less than with neutropenias associated with cancer chemotherapy.
HIV-Exposed Newborns:
  • Rare
HIV-Infected Children on ARVs:
  • 9.9%–26.8% of children on ARVs, depending upon the ARV regimen
  • Highest rates with ZDV-containing regimens
HIV-Exposed Newborns:
  • In utero exposure to ARVs
  • Concurrent ZDV plus 3TC neonatal prophylaxis
HIV-Infected Children on ARVs:
  • Advanced or poorly controlled HIV infection
  • Myelosuppressive drugs (e.g., TMP-SMX, ganciclovir, hydroxyurea, rifabutin)
HIV-Infected Children on ARVs:
  • Obtain CBC as part of routine care.
HIV-Exposed Newborns:
  • No established threshold for intervention; some experts would consider using an alternative NRTI for prophylaxis if ANC <500 cells/mm3, or discontinue ARV prophylaxis entirely if ≥4 weeks of 6-week ZDV prophylaxis have been completed (see the Perinatal Guidelinesb).
HIV-Infected Children on ARVs:
  • Discontinue non-ARV marrow-toxic drugs, if feasible.
  • Treat co-existing OIs and malignancies.
  • For persistent severe neutropenia thought to be associated with ARVs, change to a non-ZDV-containing regimen; consider a trial of G-CSF if essential to continue ZDV.
a HIV infection itself, OIs, and medications used to prevent OIs, such as TMP-SMX, may all contribute to anemia, neutropenia, and thrombocytopenia.
b Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Key to Acronyms: 3TC = lamivudine; ANC = absolute neutrophil count; ARV = antiretroviral; CBC = complete blood count; fL = femtoliter; G6PD = glucose-6-phosphate dehydrogenase; G-CSF = granulocyte colony-stimulating factor; Hgb = hemoglobin; NRTI = nucleoside reverse transcriptase inhibitor; OI = opportunistic infection; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

References

  1. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med. Jun 12 1997;336(24):1704-1712. Available at http://www.ncbi.nlm.nih.gov/pubmed/9182213.
  2. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med. Dec 16 1999;341(25):1874-1881. Available at http://www.ncbi.nlm.nih.gov/pubmed/10601506.
  3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. Nov 3 1994;331(18):1173-1180. Available at http://www.ncbi.nlm.nih.gov/pubmed/7935654.
  4. Krogstad P, Lee S, Johnson G, et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. Apr 1 2002;34(7):991-1001. Available at http://www.ncbi.nlm.nih.gov/pubmed/11880966.
  5. McKinney RE, Jr., Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. Oct 1998;133(4):500-508. Available at http://www.ncbi.nlm.nih.gov/pubmed/9787687.
  6. Najean Y, Rain JD. The mechanism of thrombocytopenia in patients with HIV infection. J Lab Clin Med. Mar 1994;123(3):415-420. Available at http://www.ncbi.nlm.nih.gov/pubmed/8133154.
  7. Caselli D, Maccabruni A, Zuccotti GV, et al. Recombinant erythropoietin for treatment of anaemia in HIV-infected children. AIDS. Jul 1996;10(8):929-931. Available at http://www.ncbi.nlm.nih.gov/pubmed/8828757.
  8. Allen UD, Kirby MA, Goeree R. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children. Pediatr AIDS HIV Infect. Feb 1997;8(1):4-11. Available at http://www.ncbi.nlm.nih.gov/pubmed/11361510.
  9. Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr. Nov 1992;121(5 Pt 1):797-802. Available at http://www.ncbi.nlm.nih.gov/pubmed/1279153.
  10. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. May 1 1991;77(9):1884-1893. Available at http://www.ncbi.nlm.nih.gov/pubmed/1850307.
  11. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. Apr 15 1997;89(8):2689-2700. Available at http://www.ncbi.nlm.nih.gov/pubmed/9108386.
  12. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J. Apr 2010;29(4):376-379. Available at http://www.ncbi.nlm.nih.gov/pubmed/19949355.
  13. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. Apr 15 2011;56(5):428-436. Available at http://www.ncbi.nlm.nih.gov/pubmed/21266910.
  14. Mocroft A, Lifson AR, Touloumi G, et al. Haemoglobin and anaemia in the SMART study. Antivir Ther. 2011;16(3):329-337. Available at http://www.ncbi.nlm.nih.gov/pubmed/21555815.
  15. Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012;12:170. Available at http://www.ncbi.nlm.nih.gov/pubmed/23114115.
  16. Esan MO, Jonker FA, Hensbroek MB, Calis JC, Phiri KS. Iron deficiency in children with HIV-associated anaemia: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. Oct 2012;106(10):579-587. Available at http://www.ncbi.nlm.nih.gov/pubmed/22846115.
  17. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. Jun 21 2012;366(25):2368-2379. Available at http://www.ncbi.nlm.nih.gov/pubmed/22716975.

Back to Top